<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="Virus Infection without Inducing Neutralizing Antibodies JE Vaccine Protects against" exact="YFV" post="Infection Mishra et al. https://orcid.org/0000-0002-8679-8847MishraNiraja*https://orcid.org/0000-0002-5984-7279BoudewijnsRobbertahttps://orcid.org/0000-0002-1137-9322SchmidMichael Alexandera*https://orcid.org/0000-0002-6949-0947MarquesRafael Eliasa*https://orcid.org/0000-0003-3493-252XSharmaSapnaahttps://orcid.org/0000-0002-0033-7514NeytsJohanahttps://orcid.org/0000-0002-8117-9166DallmeierKaia[a], KU Leuven"/>
 <result pre="a YFV-17D-based chimeric Japanese encephalitis vaccine, also efficiently protects against" exact="YFV" post="infection in mice. In case of shortage of the"/>
 <result pre="YFV infection in mice. In case of shortage of the" exact="YFV" post="vaccine during yellow fever outbreaks, (off-label) use of JE-CVax/Imojev"/>
 <result pre="JE-CVax/Imojev in Asia may lower the risk of the much-feared" exact="YFV" post="spillover to the continent. More generally, chimeric vaccines that"/>
 <result pre="emergency stockpiles and raised concerns about being unprepared against future" exact="YFV" post="epidemics. Here we report that a live attenuated virus"/>
 <result pre="SA14-14-2 vaccine strain confers full protection in mice against lethal" exact="YFV" post="challenge. In contrast to the YFV-17D-mediated protection against YFV,"/>
 <result pre="with YFV-specific nonneutralizing antibodies and T cell responses against cell-associated" exact="YFV" post="NS1 and other YFV nonstructural (NS) proteins. Our findings"/>
 <result pre="and T cell responses against cell-associated YFV NS1 and other" exact="YFV" post="nonstructural (NS) proteins. Our findings reveal the potential of"/>
 <result pre="YFV nonstructural (NS) proteins. Our findings reveal the potential of" exact="YFV" post="NS proteins to mediate protection and demonstrate that chimeric"/>
 <result pre="of JE-CVax in case of emergency and vaccine shortage during" exact="YFV" post="outbreaks. In addition, populations in Asia that have been"/>
 <result pre="have been vaccinated with Imojev may already be protected against" exact="YFV" post="should outbreaks ever occur on that continent, as several"/>
 <result pre="fever virus (YFV), Japanese encephalitis virus (JEV), dengue virus (DENV)," exact="Zika" post="virus (ZIKV), West Nile virus (WNV), and tick-borne encephalitis"/>
 <result pre="Japanese encephalitis virus (JEV), dengue virus (DENV), Zika virus (ZIKV)," exact="West Nile" post="virus (WNV), and tick-borne encephalitis virus, are important human"/>
 <result pre="a pronounced restriction to defined regions of endemicity, such as" exact="YFV" post="to sub-Saharan Africa and tropical Latin America and JEV"/>
 <result pre="suggests the first autochthonous transmission of JEV in Africa (4)." exact="Yellow fever" post="(YF) is an acute viral hemorrhagic disease which is"/>
 <result pre="highly efficient vaccine (YFV-17D; e.g., Stamaril), an estimated ∼0.2 million" exact="YFV" post="infections with 29,000 to 60,000 deaths occur annually (5)."/>
 <result pre="infections with 29,000 to 60,000 deaths occur annually (5). Recent" exact="YFV" post="outbreaks in Angola (2015-2016), the Democratic Republic of the"/>
 <result pre="outbreaks (6, 7). Since the Aedes aegypti mosquito, the main" exact="YFV" post="vector, is omnipresent in (sub)tropical Asia, YFV spillover to"/>
 <result pre="mosquito, the main YFV vector, is omnipresent in (sub)tropical Asia," exact="YFV" post="spillover to Asia and the establishment of epidemics involving"/>
 <result pre="of dengue disease by preexisting antibodies (antibody-dependent enhancement [ADE]) of" exact="DENV" post="infection (12–14). Vaccination against flaviviruses generally relies on the"/>
 <result pre="cells seem to contribute to the protective activity of current" exact="YFV" post="vaccines (16). Nonetheless, experimental evidence obtained with mice and"/>
 <result pre="Nonetheless, experimental evidence obtained with mice and nonhuman primates for" exact="YFV" post="(17–20) and, more recently, in mice also for WNV"/>
 <result pre="for YFV (17–20) and, more recently, in mice also for" exact="WNV" post="(21) and ZIKV (22) clearly shows that also nonstructural"/>
 <result pre="and, more recently, in mice also for WNV (21) and" exact="ZIKV" post="(22) clearly shows that also nonstructural (NS) proteins, in"/>
 <result pre="obviously in line with the accepted role nAbs play in" exact="YFV" post="infection. Thus, besides humoral immune responses against the E"/>
 <result pre="sequences of antigenically distinct flaviviruses (respectively, JEV and YFV-17D or" exact="DENV" post="and YFV-17D) and may therefore exert some dual protective"/>
 <result pre="to JE-CVax/Imojev provides rapidly complete protection against a massively lethal" exact="YFV" post="challenge, with a single dose being sufficient for full"/>
 <result pre="RESULTS JE-CVax provides full dual protection against lethal JEV and" exact="YFV" post="challenge in mice. JE-CVax is a c-LAV that consists"/>
 <result pre="YFV. This resulted in, respectively, 80 or 100% survival, while" exact="YFV" post="infection was uniformly lethal in all nonvaccinated controls (see"/>
 <result pre="JE-CVax (full survival in vaccinated mice) and 103 PFU of" exact="YFV" post="(full mortality in nonvaccinated mice). JE-CVax was originally developed"/>
 <result pre="resulted also in 97% survival (n = 35/36) against a massively lethal" exact="YFV" post="challenge (Fig. 1B). All placebo-vaccinated (n = 38) and Ixiaro-vaccinated (n = 12)"/>
 <result pre="&amp;gt; 0.0001). Importantly, JE-CVax also conferred similarly vigorous protection against" exact="YFV" post="in C57BL/6 wild-type (wt) mice (n = 16) against intracranial (i.c.)"/>
 <result pre="mice (n = 16) against intracranial (i.c.) challenge with 104 PFU of" exact="YFV" post="(Fig. 1D). In AG129 mice, a benefit (60% survival)"/>
 <result pre="lethal challenge (Fig. 1C). To establish that JE-CVax-mediated protection against" exact="YFV" post="is specific and not the result of some residual"/>
 <result pre="AG129 mice with 104 PFU of the more distantly related" exact="ZIKV" post="(strain MR766). No protective activity was observed (MDE for"/>
 <result pre="JE-CVax provides fast (≤14 dpv) and virus-specific protection against lethal" exact="YFV" post="exposure in mice. FIG 1 In vivo evaluation of"/>
 <result pre="Creative Commons Attribution 4.0 International license. JE-CVax mediates protection against" exact="YFV" post="without involvement of nAbs. To explore whether humoral immunity"/>
 <result pre="raised (log10 CPENT50, 1.66 ± 0.30; determined 28 days after" exact="YFV" post="exposure). Also in serum of JE-CVax- or Ixiaro-vaccinated C57BL/6"/>
 <result pre="presence (n = 8) or absence of MAR1 (n = 9) developed nAbs against" exact="YFV" post="(log10 CPENT50, 2.11 ± 0.25 or 1.78 ± 0.29,"/>
 <result pre="P ≤ 0.0001 for mean log10 CPENT50 titers against JEV or" exact="YFV" post="compared to mean log10 CPENT50 titers before JE-CVax vaccination"/>
 <result pre="are shown. 10.1128/mBio.02494-19.2FIG S2Detection of cross-reactive antibodies against JEV and" exact="YFV" post="in sera of YFV-17D-infected and JE-CVax-vaccinated mice. AG129 mice"/>
 <result pre="Ixiaro-vaccinated mice (D) were analyzed by both JEV (top) and" exact="YFV" post="(bottom) indirect immunofluorescence assay (IIFA; Euroimmun) at a magnification"/>
 <result pre="International license. JE-CVax and YFV-17D induce comparable levels of anti-NS1" exact="YFV" post="antibodies. From the IIFA analysis (Fig. S2), it is"/>
 <result pre="Serum antibodies from JE-CVax-vaccinated mice bound to cells that overexpress" exact="YFV" post="NS1 as well as to cells that had been"/>
 <result pre="that obtained when monoclonal antibody (MAb) 1A5, specifically directed against" exact="YFV" post="NS1, was used (27). JE-CVax induces YFV-specific antibodies mediating"/>
 <result pre="International license. JE-CVax induces polyfunctional T cell responses against both" exact="YFV" post="and JEV antigens. To assess whether also cellular immune"/>
 <result pre="JEV antigens. To assess whether also cellular immune response against" exact="YFV" post="may contribute to the protective activity, enzyme-linked immunosorbent spot"/>
 <result pre="AG129 and C57BL/6 mice when stimulated ex vivo with the" exact="YFV" post="NS3 peptide or YFV-17D total cellular antigen (Fig. 4D"/>
 <result pre="long-lasting T cell responses against YFV, and cellular immunity against" exact="YFV" post="was more vigorous than that elicited against JEV (Fig."/>
 <result pre="and Fig. S4 to S6). This observation is consistent with" exact="YFV" post="NS proteins serving as more immunogenic T cell antigens"/>
 <result pre="of CD4+ and CD8+ T cells in JE-CVax-mediated immunity against" exact="YFV" post="in C57BL/6 mice (n ≥ 7) that had been vaccinated with"/>
 <result pre="i.p. on day −2 and day 0 each prior to" exact="YFV" post="challenge. Log rank (Mantel-Cox) survival analysis test was performed"/>
 <result pre="to CD4-depleted group (n = 8). 10.1128/mBio.02494-19.4FIG S4T cell responses directed against" exact="YFV" post="or JEV antigens in ELISpot assay. Representative wells of"/>
 <result pre="vivo restimulation with an MHC class I-restricted peptide derived from" exact="YFV" post="NS332 or the lysate of YFV-17D- or JEV SA14-14-2-infected"/>
 <result pre="antibodies twice, i.e., 2 days before and immediately prior to" exact="YFV" post="challenge. Unlike for vaccinated (but not further treated) animals"/>
 <result pre="included as immunization controls [n = 5] and that survived an intracranial" exact="YFV" post="challenge), in vaccinated but antibody-treated mice the previously observed"/>
 <result pre="vaccinated but antibody-treated mice the previously observed full protection against" exact="YFV" post="was partially lost by targeting CD4+ (n = 1/8), CD8+ (n = 3/7),"/>
 <result pre="4E). All nonvaccinated animals (n = 5; P = 0.0027) succumbed to" exact="YFV" post="challenge as before (Fig. 1D). The mortality resulting from"/>
 <result pre="and CD8+ T cells contribute to the JE-CVax-mediated protection against" exact="YFV" post="in C57BL/6 mice. CTL epitopes within the YFV-17D NS"/>
 <result pre="YFV-17D-vaccinated controls. Similarly, 80% protection against challenge with the African" exact="YFV" post="strain Dakar 1279 was observed in monkeys following repeated"/>
 <result pre="whether it can offer, besides protection against JEV, protection against" exact="YFV" post="challenge. Since AG129 mice are highly susceptible to lethal"/>
 <result pre="strains as established surrogates for wt JEV (33) and wt" exact="YFV" post="(34, 35), respectively (demanding lower biosafety containment for handling)."/>
 <result pre="protection (35, 36) against a massive (1,000 LD50] challenge with" exact="YFV" post="(Fig. 1B). The protective activity against YFV was raised"/>
 <result pre="LD50] challenge with YFV (Fig. 1B). The protective activity against" exact="YFV" post="was raised fast, and a survival benefit could be"/>
 <result pre="complete protection (21/21) against lethal intracranial challenge (17, 23) with" exact="YFV" post="(Fig. 1D and Fig. 4E). This activity of JE-CVax"/>
 <result pre="(Fig. 1D and Fig. 4E). This activity of JE-CVax was" exact="YFV" post="specific, as AG129 mice that had been vaccinated with"/>
 <result pre="Ixiaro (the inactivated JEV vaccine) were not protected against lethal" exact="YFV" post="challenge. Furthermore, mice that had been vaccinated with JE-CVax"/>
 <result pre="that had been vaccinated with JE-CVax and that later survived" exact="YFV" post="challenge did not survive a subsequent lethal challenge with"/>
 <result pre="challenge did not survive a subsequent lethal challenge with the" exact="ZIKV" post="(Fig. S1). 10.1128/mBio.02494-19.7FIG S7In vivo infectivity of YFV-17D and"/>
 <result pre="JEV-P3 strain-based inactivated vaccine and JEV SA14-14-2)-vaccinated mice challenged with" exact="DENV" post="(26). Likewise, a chimeric Japanese encephalitis/dengue virus 2 experimental"/>
 <result pre="considerable levels of E-specific partially cross-reactive nAbs that neutralized both" exact="DENV" post="and JEV. Additionally, the study (31) demonstrated that vaccination"/>
 <result pre="T cell responses could obviously not be distinguished from what" exact="DENV" post="NS proteins may contribute. In contrast, although we also"/>
 <result pre="In contrast, although we also observed some residual cross-reactivity for" exact="YFV" post="in serum samples of JE-CVax-vaccinated mice (binding antibody in"/>
 <result pre="S2]), JE-CVax failed to induce any detectable nAb titers against" exact="YFV" post="even following repeated boosting (Fig. 2A). This finding is"/>
 <result pre="were variations in the actual levels of anti-YFV nAbs after" exact="YFV" post="challenge. In some animals, no nAbs were detected against"/>
 <result pre="YFV challenge. In some animals, no nAbs were detected against" exact="YFV" post="after YFV-17D-challenge. This lack of YFV nAb indicates that"/>
 <result pre="nAbs were detected against YFV after YFV-17D-challenge. This lack of" exact="YFV" post="nAb indicates that JE-CVax possibly conferred sterilizing immunity in"/>
 <result pre="with anti-NS1 antibodies) to be involved in JE-CVax-mediated protection against" exact="YFV" post="(Fig. 4E). Previously, only humoral immunity and CD4+ T"/>
 <result pre="been implied to be sufficient and required for protection against" exact="YFV" post="(16), with a strong emphasis on nAb as a"/>
 <result pre="nAb as a historically established immunological correlate of protection for" exact="YFV" post="(5) and for flaviviruses (such as JEV) in general"/>
 <result pre="an Fc-dependent manner (for example, via ADCC toward cells expressing" exact="YFV" post="NS1 on their surfaces) (18, 21, 43, 44). Indeed,"/>
 <result pre="of AG129 and C57BL/6 mice with JE-CVax elicited protective polyfunctional" exact="YFV" post="antigen-specific CD4+ and CD8+ T cell responses (expressing the"/>
 <result pre="demonstrated that vaccination with CYD-TDV/Dengvaxia elicits cell-mediated immunity directed against" exact="YFV" post="nonstructural proteins (46, 47). Our comparative in silico analysis"/>
 <result pre="Collectively, our data suggest that JE-CVax-mediated vigorous protection against lethal" exact="YFV" post="challenge depends on the combined effects of several effector"/>
 <result pre="can hence be considered a genuine mouse-adapted neurotropic and neurovirulent" exact="YFV" post="strain. For this reason, it could also be considered"/>
 <result pre="Therefore, in conclusion, similar mechanisms should hold when using wild-type" exact="YFV" post="as the challenge virus (44, 52). Obviously, before proceeding"/>
 <result pre="nonhuman primates, demonstrating protection from subsequent challenge with virulent wt" exact="YFV" post="strains. Live attenuated JE SA14-14-2 and inactivated Vero cell"/>
 <result pre="to address whether Imojev will also induce protective immunity against" exact="YFV" post="in those that have already been vaccinated with one"/>
 <result pre="dual protective effect may be of particular relevance in case" exact="YFV" post="may one day—as is suspected (8, 9)—cause outbreaks in"/>
 <result pre="Given the capacity problems with the production of the current" exact="YFV" post="vaccine, having another licensed vaccine (i.e., JE-CVax/Imojev) available as"/>
 <result pre="(i.e., JE-CVax/Imojev) available as an alternative means to protect against" exact="YFV" post="may at such time help to contain an outbreak."/>
 <result pre="YFV-17D/ZIKV vaccine candidate) (28). Likewise, c-LAVs could be generated against" exact="DENV" post="and other viruses that may cause ADE using the"/>
 <result pre="viruses or serotypes, in line with experimental evidence that the" exact="DENV" post="NS1 protein can also serve as a protective antigen"/>
 <result pre="nAb responses. The same principle may apply to c-LAV for" exact="ZIKV" post="using a ZIKV backbone (58) and prM/E sequences of"/>
 <result pre="same principle may apply to c-LAV for ZIKV using a" exact="ZIKV" post="backbone (58) and prM/E sequences of another flavivirus that"/>
 <result pre="and rapidly induces high cross-protective efficacy (∼100%) in mice against" exact="YFV" post="challenge, even with an exceedingly aggressive challenge inoculum. The"/>
 <result pre="cells to generate virus stocks. As an alternative challenge virus," exact="ZIKV" post="strain MR766 was used (60). Virus titers were determined"/>
 <result pre="serving as a well-established surrogate rodent challenge model for wt" exact="YFV" post="infection (34, 35, 74). Six- to 8-week-old male AG129"/>
 <result pre="JE-CVax and YFV-17D were performed. We did not observe any" exact="YFV" post="nAbs in the hyperimmune sera but did see an"/>
 <result pre="of YFV-17D. At day −2 and day 0 prior to" exact="YFV" post="challenge, 0.5 mg of either anti-mouse CD4 (clone GK1.5; Leinco"/>
 <result pre="To determine the seroconversion of animals, all JEV, YFV, and" exact="ZIKV" post="IgG indirect immunofluorescence assays (IIFAs) were performed as per"/>
 <result pre="good correlation (Pearson correlation [R2] = 0.071; P = 0.02) between log10" exact="YFV" post="PRNT50 and log10 YFV CPENT50 of matched samples (A)."/>
 <result pre="[R2] = 0.071; P = 0.02) between log10 YFV PRNT50 and log10" exact="YFV" post="CPENT50 of matched samples (A). There was no marked"/>
 <result pre="Creative Commons Attribution 4.0 International license. ELISA. Serum antibodies recognizing" exact="YFV" post="NS1 were detected by indirect enzyme-linked immunosorbent assay (ELISA),"/>
 <result pre="MaxiSorp; Thermo Fisher Scientific) were coated with 1 μg/ml of recombinant" exact="YFV" post="NS1 (Bio-Rad; catalog no. PIP052A) in 50 mM carbonate buffer"/>
 <result pre="for 2 h at room temperature. Serial dilutions of the" exact="YFV" post="NS1-specific mouse IgG2a monoclonal antibody (clone 1A5, kindly provided"/>
 <result pre="positive. ADCC bioassay. To assess the possible role of nonneutralizing" exact="YFV" post="antibody-mediated protection against YFV after JE-CVax vaccination, antibody-dependent cell-mediated"/>
 <result pre="assess the possible role of nonneutralizing YFV antibody-mediated protection against" exact="YFV" post="after JE-CVax vaccination, antibody-dependent cell-mediated cytotoxicity (ADCC) bioassays (29)"/>
 <result pre="cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of" exact="West Nile" post="virus-infected cells. J Virol81:9551–9555. doi:10.1128/JVI.00879-07.17582005 22.BaileyMJ, BroeckerF, DuehrJ, ArumemiF,"/>
 <result pre="PaleseP, TanGS2019Antibodies elicited by an NS1-based vaccine protect mice against" exact="Zika" post="virus. mBio10:e02861-18. doi:10.1128/mBio.02861-18.30940710 23.BassiMR, LarsenMA, KongsgaardM, RasmussenM, BuusS, StryhnA,"/>
 <result pre="NeytsJ, DallmeierK2018A yellow fever-Zika chimeric virus vaccine candidate protects against" exact="Zika" post="infection and congenital malformations in mice. NPJ Vaccines3:56. doi:10.1038/s41541-018-0092-2.30564463"/>
 <result pre="GrifoniA, DiamondMS, SetteA, PetersB2016Identifying candidate targets of immune responses in" exact="Zika" post="virus based on homology to epitopes in other flavivirus"/>
 <result pre="YangY, MuruatoAE, ZouJ, ShanC, NunesBT, MedeirosDB, VasconcelosPF, WeaverSC, RossiSL, ShiPY2017Understanding" exact="Zika" post="virus stability and developing a chimeric vaccine through functional"/>
 <result pre="polymerase inhibitor 7-deaza-2′-c-methyladenosine is a potent inhibitor of in vitro" exact="Zika" post="virus replication and delays disease progression in a robust"/>
 <result pre="MasonPW, BloomME, García-SastreA, KhromykhAA, BestSM2010The NS5 protein of the virulent" exact="West Nile" post="virus NY99 strain is a potent antagonist of type"/>
</results>
